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Abstract
The bioactive sphingolipid sphingosine 1-phosphate (S1P) is found in increased amounts in the airways of asthmatics. S1P
can regulate airway smooth muscle functions associated with asthmatic inflammation and remodeling, including cytokine
secretion. To date however, whether S1P induces secretion of an important chemokine responsible for neutrophilia in
airway inflammation – IL-8 – was unexplored. The aim of this study was to investigate whether S1P induces IL-8 gene
expression and secretion to enhance neutrophil chemotaxis in vitro, as well as examine the molecular mechanisms
responsible for repression by the corticosteroid dexamethasone. We show that S1P upregulates IL-8 secretion from ASM
cells and enhance neutrophil chemotaxis in vitro. The corticosteroid dexamethasone significantly represses IL-8 mRNA
expression and protein secretion in a concentration- and time-dependent manner. Additionally, we reveal that S1P-induced
IL-8 secretion is p38 MAPK and ERK-dependent and that these key phosphoproteins act on the downstream effector
mitogen- and stress-activated kinase 1 (MSK1) to control secretion of the neutrophil chemoattractant cytokine IL-8. The
functional relevance of this in vitro data was demonstrated by neutrophil chemotaxis assays where S1P-induced effects can
be significantly attenuated by pretreatment with dexamethasone, pharmacological inhibition of p38 MAPK- or ERK-
mediated pathways, or by knocking down MSK-1 with siRNA. Taken together, our study reveals the molecular pathways
responsible for IL-8 secretion from ASM cells in response to S1P and indicates ways in which the impact on IL-8-driven
neutrophilia may be lessened.
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Introduction
Asthma can be considered a heterogeneous syndrome made up
of a number of disease phenotypes characterized by their
underlying pathophysiology into ‘‘asthma endotypes’’ [1,2].
Defining asthma in this way will enable the design of tailored
therapeutic strategies that specifically target the fundamental
mechanisms responsible for the disease endotypes. One important
asthma endotype is non-eosinophilic (neutrophilic) asthma. Neu-
trophilic asthma is driven by the chemokine CXCL8 (IL-8) [3];
thus studies into the molecular pathways that upregulate this
neutrophil chemoattractant will allow us to gain greater insight
into the underlying pathogenic mechanisms and suggest potential
pharmacotherapeutic strategies for treating the neutrophilic
asthma endotype in the future.
The causes of neutrophilic asthma are currently uncertain.
Innate immunity dysregulation through TLR2 plays an important
role [4], as may Th17 regulation [5] and NLRP3 inflammasome
activation [6]. Activation of these cellular pathways has been
reported to increase neutrophilic inflammation in the airways in
an IL-8-driven manner; key characteristics of the disease
endotype. Airway structural cells (such as alveolar epithelium
and airway smooth muscle (ASM)) serve as important contributors
to IL-8 chemokine production and in this way may orchestrate
neutrophil chemoattraction in response to inflammatory mediators
[7–9].
In this study we focus on ASM cells in order to examine
whether IL-8 is produced in response to stimulation with
sphingosine 1-phosphate (S1P). S1P is a bioactive sphingolipid
found elevated in the airways of asthmatics [10] and can increase
IL-8 secretion from human alveolar epithelial cells (A549) to
regulate neutrophil–epithelial interactions in vitro [11]. Herein we
are the first to show that S1P induces IL-8 secretion from ASM
cells and demonstrate the molecular mechanisms responsible. We
show that the anti-inflammatory corticosteroid dexamethasone
inhibits S1P-induced IL-8 driven neutrophil chemotaxis and show
that the molecular pathways responsible for corticosteroid-
mediated repression converge on mitogen- and stress-activated
kinase 1 (MSK1). These studies may provide further insight into




Human bronchi were obtained from patients undergoing
surgical resection for carcinoma or lung transplant donors in
accordance with procedures approved by the Sydney South West
Area Health Service and the Human Research Ethics Committee
of the University of Sydney. Written informed consent from the
donor was obtained for use of this sample in research. ASM cells
were dissected, purified and cultured as previously described by
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Johnson et al. [12]. A minimum of three different ASM primary
cell lines were used for each experiment.
Chemicals
S1P (Biomol) was purchased through Enzo Life Sciences
(Exeter, UK) and tumor necrosis factor a (TNFa) purchased from
R&D Systems (Minneapolis, MN). Unless otherwise specified, all
chemicals were from Sigma-Aldrich (St. Louis, MO).
ELISAs
Cell supernatants were collected and stored at 220uC for later
analysis by ELISA. IL-8 ELISAs were performed according to the
manufacturer’s instructions (BD Biosciences Pharmingen, San
Diego, CA).
Real-time RT-PCR
Total RNA was extracted using the RNeasy Mini Kit (Qiagen
Australia, Doncaster, VIC, Australia) and reverse transcription
performed by using the RevertAid First strand cDNA Synthesis
Kit (Fermentas Life Sciences, Hanover, MD) as per the
manufacturer’s protocol. MKP-1 mRNA levels were measured
using real-time RT-PCR on an ABI Prism 7500 (Applied
Biosystems, Foster City, CA) with the IL-8 (Hs00174103_m1)
TaqManH Gene Expression Assay and the eukaryotic 18S rRNA
endogenous control probe (Applied Biosystems) subjected to the
following cycle parameters: 50uC for 2 min, 1 cycle; 95uC for
10 min, 1 cycle; 95uC for 15 s, 60uC for 1 min, 40 cycles.
NF-kB activity assays
NF-kB activity assays were performed with the NF-kB reporter
vector, pNF-kB-Luc, according to our previously published
methods [7,13].
siRNA knock-down
ASM cells were transiently transfected using nucleofection with
1 mg MSK1-specific SMART pool siRNA as described previously
[14] and cell supernatants removed for IL-8 protein measurement
by ELISA and lysates utilized for MSK1 Western blotting (Cell
Signaling Technology, Danvers, MA) [14].
Neutrophil chemotaxis
Neutrophils were purified from anti-coagulated venous blood of
a healthy volunteer by positive selection using magnetic-activated
cell sorting (MACS) as previously described [15]. Written
informed consent from the volunteer was obtained for use of this
sample in research in accordance with procedures approved by the
Human Research Ethics Committee of the University of Sydney.
Briefly, erythrocytes were removed by dextran sedimentation
Figure 1. The bioactive sphingolipid S1P induces secretion of IL-8 from ASM cells, but this can be repressed by the corticosteroid
dexamethasone in a concentration-dependent manner. (A) Growth-arrested ASM cells were treated with vehicle or S1P (1 mM) for 24 h and IL-
8 secretion measured by ELISA. Statistical analysis was performed using the Student’s unpaired t test, where 1 denotes a significant effect of S1P (P,
0.05). (B) To demonstrate corticosteroid-mediated repression of S1P-induced IL-8 secretion we then pretreated growth-arrested ASM cells for 1 h with
vehicle or dexamethasone (0.0001-1M), before stimulation for 24 h with S1P (1 mM). IL-8 protein was measured by ELISA and results expressed as %
S1P-induced IL-8 secretion at 24 h. Statistical analysis was performed using one-way ANOVA then Fisher’s post-hoc multiple comparison test, where
* denotes significant repression by dexamethasone (P,0.05). Data are mean+SEM values from n= 12 primary ASM cell lines.
doi:10.1371/journal.pone.0092466.g001
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followed by ficoll centrifugation to separate mononuclear cells
from granulocytes. Remaining erythrocytes were lysed by osmotic
shock and the pellet which contains eosinophils/neutrophils was
mixed with anti-CD16 conjugated immunomagnetic beads
(Miltenyi Biotec, Sunnyvale, CA) and incubated for 30 min at
4uC. The cells were then separated using MACS where the eluant
was discarded. Neutrophils bound to the micro-beads were taken
out of the magnetic field, flushed and prepared at a cell density of
26106/ml in DMEM+0.1% BSA to be used in chemotaxis assays.
Neutrophil chemotaxis towards conditioned media from treated
ASM cells was quantified microscopically using a 96-well
microchemotaxis chamber (Neuroprobe, Gaithersburg, MD) as
previously published [7].
Statistical analysis
Statistical analysis was performed using Student’s unpaired t
test, one-way ANOVA then Fisher’s post-hoc multiple comparison
test, or two-way ANOVA then Bonferroni’s post-test. P values ,
0.05 were sufficient to reject the null hypothesis for all analyses.
Results
The bioactive sphingolipid S1P induces secretion of IL-8
from ASM cells, but this can be repressed by the
corticosteroid dexamethasone in a concentration-
dependent manner
Our previous studies have shown that the bioactive sphingolipid
S1P is increased in the airways of asthmatics [10] and as airway
neutrophilia has shown to be linked to asthmatic inflammation we
were interested to explore whether S1P increases secretion of the
neutrophilic chemoattractant IL-8 from ASM cells. To address
this, ASM cells were stimulated with 1 mM S1P for 24 h and the
resultant IL-8 secretion measured by ELISA. As shown in
Figure 1A, S1P significantly increases secretion of IL-8 (P,0.05).
Importantly, S1P-increased IL-8 secretion from ASM cells can be
repressed by the corticosteroid dexamethasone in a concentration-
dependent manner (Figure 1B: P,0.05).
Time course of S1P-induced IL-8 mRNA expression and
protein secretion and its repression by dexamethasone
In order to explore the molecular mechanism of repression by
dexamethasone we first performed an analysis of the temporal
kinetics of S1P-induced IL-8 mRNA expression and subsequent
protein secretion and its repression by dexamethasone. As shown
in Figure 2A, S1P robustly increases IL-8 mRNA expression as
early as 1 h after stimulation. This expression is sustained from 2-
8 h, before receding to baseline levels by 24 h (P,0.05). This
upregulation is repressed by dexamethasone pretreatment with
S1P-induced IL-8 mRNA expression being significantly inhibited
by dexamethasone at 2 h (P,0.05). The pattern of protein
secretion follows the same course with significant amounts of IL-8
being secreted from ASM cells by 8 h and accumulating further at
24 h (Figure 2B: P,0.05). Secretion of IL-8 was substantially and
significantly repressed by the corticosteroid dexamethasone at
24 h (Figure 2B: P,0.05).
Figure 2. Time course of S1P-induced IL-8 mRNA expression and protein secretion and its repression by dexamethasone. Growth-
arrested ASM cells were pretreated for 1 h with vehicle or 100 nM dexamethasone, followed by treatment with vehicle or S1P (1 mM) for 0, 1, 2, 4, 8,
and 24 h. (A) IL-8 mRNA expression was quantified by real-time RT-PCR and results expressed as fold increase compared to vehicle-treated cells at
0 h. (B) IL-8 protein secretion was measured by ELISA and results expressed as % S1P-induced IL-8 secretion at 24 h. Statistical analysis was performed
using two-way ANOVA then Bonferroni’s post-test where * indicates significant repression by dexamethasone, compared to vehicle-treated cells at
the same time point (P,0.05). Data are mean+SEM values from n=7 primary ASM cell lines.
doi:10.1371/journal.pone.0092466.g002
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Figure 3. Dexamethasone totally inhibits S1P-induced IL-8 protein secretion, but only partially inhibits TNFa-induced IL-8 induced
in the presence of S1P. (A) To compare IL-8 secretion, growth-arrested ASM cells were treated with vehicle, S1P (1 mM), TNFa (10 ng/ml), or S1P
(1 mM) in combination with TNFa (10 ng/ml). (B–C) To examine the relative corticosteroid sensitivity, cells were pretreated for 1 h with vehicle or
dexamethasone (0.0001, 0.01, 1 mM) then: (B) stimulated with S1P (1 mM); (C) stimulated with TNFa (10 ng/ml); (D) stimulated with S1P (1 mM) +TNFa
(10 ng/ml). After 24 h, secreted IL-8 was measured by ELISA. Statistical analysis was performed using one-way ANOVA then Fisher’s post-hoc multiple
comparison test, where 1 denotes a significant upregulation of IL-8, and * denotes a significant effect of dexamethasone on IL-8 secretion (P,0.05).
Data are mean+SEM values from n=7 primary ASM cell lines.
doi:10.1371/journal.pone.0092466.g003
Figure 4. S1P does not activate NF-kB in ASM cells. ASM cells
transfected with a NF-kB reporter vector, pNF-kB-Luc, were growth-
arrested, then treated with vehicle or TNFa (10 ng/ml), in the absence
or presence of S1P (1 mM) for 6 h. Cells were then harvested and
luciferase and b-galactosidase activities assessed. Data represent
normalized luciferase activity, relative to vehicle-treated cells (expressed
as fold difference). Statistical analysis was performed using the
Student’s unpaired t test (where 1 denotes significant effect of TNFa
on NF-kB activity (P,0.05)). Data are mean+SEM values from n=6
primary ASM cell lines.
doi:10.1371/journal.pone.0092466.g004
Figure 5. S1P-induced IL-8 protein secretion is repressed by
inhibitors of the p38 MAPK- and ERK-mediated pathways.
Growth-arrested ASM cells were pretreated for 30 min with vehicle,
1 mM SB203580, or 10 mM PD98059 to inhibit p38 MAPK and ERK,
respectively. Cells were then stimulated with 1 mM S1P for 24 h. IL-8
protein was measured by ELISA and results expressed as % S1P-induced
IL-8 secretion at 24 h. Statistical analysis was performed using the
Student’s unpaired t test, where * denotes significant inhibition (P,
0.05). Data are mean+SEM values from n= 10 primary ASM cell lines.
doi:10.1371/journal.pone.0092466.g005
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Dexamethasone totally inhibits S1P-induced IL-8 protein
secretion, but only partially inhibits TNFa-induced IL-8
induced in the presence of S1P
As we had observed (in Figures 1 & 2) that dexamethasone
represses S1P-induced IL-8 expression relatively effectively, S1P
secretion alone cannot solely account for the more corticosteroid
insensitive phenotype associated with neutrophilic asthma. As
numerous inflammatory mediators can be found elevated in
asthma at the same time, it is of interest to examine the relative
corticosteroid sensitivity of IL-8 induced by another inflammatory
mediator added in combination with S1P. TNFa is a key example
[16]. Therefore we stimulated cells with S1P+TNFa in order to
determine if the model is more corticosteroid resistant under these
experimental conditions. We first performed a side-by-side
comparison of IL-8 secretion in response to S1P or TNFa, added
separately or in combination. As shown in Figure 3A, and in
confirmation of our earlier studies [7], TNFa potently and
significantly increases IL-8 secretion. Notably, TNFa-induced IL-8
secretion is significantly potentiated in the presence of S1P
(Figure 3A: P,0.05). We then compared the relative corticosteroid
sensitivity of IL-8 induced by each stimulant, alone or in
combination. As shown in Figure 3B, IL-8 induced by S1P can
be completely repressed by dexamethasone. Dexamethasone
concentrations as low as 0.01 mM can repress S1P-induced IL-8
secretion to unstimulated levels. In contrast, TNFa-induced IL-8
cannot be is relatively resistant to repression by dexamethasone
(Figure 3C). Even after 1 mM dexamethasone pretreatment,
TNFa-induced IL-8 secretion cannot be completely repressed
(Figure 3C). Accordingly, when then the two pro-inflammatory
mediators are added together, S1P in addition to the potent pro-
inflammatory cytokine TNFa induces IL-8 expression that is
relatively corticosteroid resistant (Figure 3D).
S1P does not activate NF-kB in ASM cells
In order to examine whether the difference in corticosteroid
sensitivity between mediators is due to the involvement of NF-kB
signaling pathway in mediating IL-8 expression we utilized an NF-
kB reporter vector, pNF-kB-Luc. As shown in Figure 4, TNFa
activates NF-kB; in confirmation of our earlier studies [17].
Importantly, S1P alone does not increase NF-kB-luciferase
activity, nor increase TNFa-induced NF-kB activity. As NF-kB
activity in ASM cells is relatively insensitive to repression by
corticosteroids [18–20], our in vitro results may reflect the in vivo
situation where multiple inflammatory mediators orchestrate
chemokine expression and is consistent with airway neutrophilia
being corticosteroid resistant.
S1P-induced IL-8 protein secretion is repressed by
inhibitors of the p38 MAPK- and ERK-mediated pathways
We had previously shown that S1P rapidly activates all
members of the MAPK superfamily [21] and had earlier
implicated p38 MAPK and ERK pathways in IL-8 secretion in
response to another stimulus – TNFa [13]. For these reasons we
now explored the role of the p38 MAPK and ERK pathways in
S1P-induced IL-8 secretion. We utilized well-established pharma-
cological inhibitors of p38 MAPK and ERK, i.e. 1 mM
SB2035680 and 10 mM PD98059, respectively, and investigated
their repressive effects on S1P-induced IL-8 protein secretion from
ASM cells. We routinely utilize these inhibitors to repress p38
MAPK and ERK signaling in ASM cells in vitro [7,13,14,20,22,23]
as they specifically inhibit p38 MAPK and ERK phosphorylation
in ASM cells at these concentration [21]. As shown in Figure 5,
S1P-induced IL-8 protein secretion was significantly repressed by
both SB203580 and PD98059 pretreatment (P,0.05).
IL-8 induced by S1P causes human neutrophil
chemotaxis in vitro and this can be repressed by
corticosteroids or by blocking the p38 MAPK- or ERK-
mediated pathways
Taken together, our results thus far demonstrate that S1P
induces IL-8 secretion from ASM cells and that this secretion can
be repressed by the corticosteroid dexamethasone and pharma-
cological inhibitors of the mitogen- and stress-activated protein
kinases; p38 MAPK and ERK. IL-8 is a key neutrophil
chemoattractant cytokine and in Figure 6 we show that human
neutrophils undergo significant chemotaxis towards conditioned
media from cells stimulated with S1P. Importantly, this S1P-
induced chemotaxis was significantly reduced when cells were
pretreated with dexamethasone, SB203580 or PD98059 prior to
S1P stimulation (Figure 6: P,0.05). These data suggest that the
bioactive sphingolipid S1P may play a role in IL-8-driven
Figure 6. IL-8 induced by S1P causes human neutrophil chemotaxis in vitro and this can be repressed by corticosteroids or by
blocking the p38 MAPK- or ERK-mediated pathways. Chemotaxis of human neutrophils toward conditioned media from growth-arrested ASM
cells pretreated with vehicle, dexamethasone (100 nM), SB203580 (1 mM) or PD98059 (10 mM), followed by treatment with vehicle or S1P (1 mM) for
24 h, was measured using microchemotaxis chambers. Results are expressed as cells per high-power (x200) field. Statistical analysis was performed
using the Student’s unpaired t test where 1 denotes a significant effect of S1P on neutrophil chemotaxis, while * denotes significant repression (P,
0.05). Data are mean+SEM values using conditioned media from n= 3 primary ASM cell lines.
doi:10.1371/journal.pone.0092466.g006
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neutrophilic inflammation and implicate molecular pathways that
may be targeted to reduce expression of this chemokine.
S1P induces IL-8 secretion via a MSK1-dependent
pathway and MSK1 knock-down by siRNA attenuates
S1P-induced neutrophil chemotaxis
S1P-induced IL-8 is mediated via p38 MAPK and ERK-
mediated pathway. One of the important downstream effectors of
these mitogen- and stress-activated kinases is MSK1. We have
recently demonstrated that S1P activation leads to MSK1
phosphorylation in ASM cells [14]. Thus, to address whether
S1P-induced IL-8 secretion is mediated via a MSK1-dependent
pathway we transiently transfected ASM cells using nucleofection
with scrambled control or MSK1 siRNA and assessed the impact
of reduced MSK1 on IL-8 secretion induced by S1P. Figure 7A
demonstrates successful knock-down of MSK1 with siRNA. As
shown in Figure 7B, the degree of IL-8 secretion was significantly
less in cells transfected with MSK1 siRNA as compared to
scrambled control (P,0.05). Accordingly, by reducing S1P-
induced IL-8 secretion MSK1 knock-down also reduces S1P-
induced neutrophil chemotaxis. This is demonstrated in Figure 7C,
where neutrophil chemotaxis in supernatants from cells nucleo-
fected with MSK1 siRNA was 57.2618.2% when compared to
supernatants from scrambled control cells (designated as
100%)(P,0.05).
Discussion
S1P is found elevated in airways of asthmatics and in this study
we explore its stimulatory effect on an important chemokine
responsible for neutrophilia in airway inflammation – IL-8. We
demonstrate that stimulation of ASM cells with S1P results in IL-8
gene expression and protein secretion. We determine the temporal
kinetics of IL-8 upregulation and show that mRNA expression and
protein secretion can be repressed by the corticosteroid dexa-
methasone. Additionally, we reveal that S1P-induced IL-8
secretion is p38 MAPK- and ERK-dependent and that these key
phosphoproteins act on the downstream effector MSK1 to control
secretion of the neutrophil chemoattractant cytokine IL-8. We
demonstrate the functional relevance of our in vitro data by
performing neutrophil chemotaxis assays. We show that S1P-
induced effects can be significantly attenuated by pretreatment
with dexamethasone, pharmacological inhibition of p38 MAPK-
or ERK-mediated pathways, or by knocking down MSK-1 with
siRNA. Taken together these studies help us appreciate the
molecular pathways responsible for IL-8 secretion from ASM cells
in response to S1P and indicate ways in which its impact on IL-8-
driven neutrophilia may be repressed.
S1P is increasingly recognized as playing an important role in
asthma and airway inflammation. We were the first to show that
the levels of this bioactive sphingolipid were increased in the
broncho-alveolar lavage fluid of allergic asthmatics [10] and since
that time the important immunomodulatory role for S1P in
asthma and airway remodeling has clearly emerged (reviewed in
[24–26]). The source of S1P in allergic asthma is considered to be
the mast cell [25,27]. This is of relevance to the current study,
where we focus on the immunostimulatory effects of S1P on
airway structural cells, because we have previously shown that
increased numbers of mast cells are close proximity to ASM in
airways of sensitized individuals [28]; a finding confirmed in the
airways of asthmatics [29]. These studies suggest that S1P released
from mast cells may act upon the surrounding airway tissue to
initiate, perpetuate or perhaps amplify airway responses, including
cytokine secretion. In support, we have previously shown that S1P
Figure 7. S1P induces IL-8 secretion via a MSK1 dependent
pathway and MSK1 knock-down by siRNA attenuates S1P-
induced neutrophil chemotaxis. ASM cells were transiently
transfected using nucleofection with scrambled control or MSK1 siRNA,
growth-arrested, then treated for 24 h with vehicle or S1P (1 mM). (A) To
confirm that MSK1 siRNA reduces protein levels of MSK1, cells were
lysed and immunoblotted for MSK1, using a-tubulin as the loading
control. To measure the effect of MSK1 knock-down on IL-8 inducibility
and neutrophil chemotaxis, supernatants were removed and (B) IL-8
protein measured by ELISA and (C) neutrophil chemotaxis assessed
using microchemotaxis chambers. Results are expressed as: (A)
representative Western blots; (B) % S1P-induced IL-8 secretion in cells
transfected with scrambled control; or (C) % S1P-induced neutrophil
chemotaxis in the corresponding conditioned media (data are mean+
SEM values from n= 6 primary ASM cell lines). Statistical analysis was
performed using the Student’s unpaired t test where * indicates that
knocking down MSK-1 significantly attenuates S1P-induced effects (P,
0.05).
doi:10.1371/journal.pone.0092466.g007
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potently induces secretion of IL-6 from ASM [10,14] and herein
show that expression of IL-8 is also stimulated by S1P. Our study
is in accord with a recent publication that demonstrated that S1P
also enhanced IL-8 secretion from alveolar epithelial cells [11].
These studies suggest that the bioactive sphingolipid S1P can
orchestrate cytokine production in airway inflammation and in the
current study we extend our investigation to demonstrate that S1P
can enhance neutrophil chemoattraction. This study is of clinical
relevance given the contribution of airway neutrophilia to asthma
pathophysiology.
Our recent papers in ASM cells have highlighted some of the
key signaling pathways activated by S1P in ASM cells. S1P rapidly
activates all members of the MAPK superfamily and also induces
robust and sustained phosphorylation of the cAMP-dependent
transcription factor CREB [14,21]. Taken together with the
knowledge that IL-8 secretion from ASM cells can be inhibited by
SB203580 and PD98059 [13], but is independent of the cAMP/
CREB-mediated pathway [30], we were able to narrow our focus
for investigation in this study and reveal for the first time that S1P-
induced IL-8 secretion is mediated by p38 MAPK- and ERK-
dependent pathways. This is important as we have recently shown
that the downstream effector of these mitogen- and stress-activated
protein kinases – MSK1 - plays an essential role in controlling
histone H3 phosphorylation, enhanced chromatin relaxation and
regulation of gene expression. Thus, by stimulating p38 MAPK/
ERK, S1P induces IL-8 expression in ASM cells in an MSK1-
dependent pathway. This was confirmed by knocking-down
MSK1 with siRNA and showing that S1P-induced IL-8 secretion
was attenuated.
Our study also reveals that the corticosteroid dexamethasone
can reduce S1P-induced IL-8 gene expression, and resultant
protein secretion, in a time- and concentration-dependent
manner. Our recent study [14] explored the signaling pathways
responsible for secretion of another cytokine released by ASM cells
after S1P stimulation, namely IL-6, and revealed how corticoste-
roids act to exert their anti-inflammatory effects. We know now
that corticosteroids mediate their anti-inflammatory actions, in
part, via upregulation of the anti-inflammatory protein-MKP-1
(mitogen-activated protein kinase phosphatase 1) [14,20,31].
Importantly, inhibition of the MSK1/histone H3 pathways is
one of the key ways in which corticosteroids mediate their
repressive effects in ASM cells. This was shown in our recent study
[14] where corticosteroid-induced MKP-1 attenuated S1P-
induced IL-6 secretion by dephosphorylating p38 MAPK and
ERK-mediated activation of MSK1 and histone H3 phosphory-
lation. We propose that S1P-induced IL-8 is controlled in a similar
MSK1-dependent manner. We illustrate the clinical relevance of
targeting MSK1 by demonstrating that knocking-down MSK1
significantly represses IL-8-driven neutrophil chemotaxis induced
by S1P. Thus MSK1 inhibition may represent a feasible
therapeutic option for controlling S1P-mediated pro-inflammatory
actions in the future.
The role of neutrophils in airway inflammation has recently
come to the fore and therefore in this study we examined whether
the asthma-related sphingolipid S1P increased secretion of the
neutrophil chemoattractant IL-8 from ASM cells. Demonstration
of S1P-induced neutrophil chemotaxis is clinically relevant given
the important role played by IL-8-driven airway neutrophilia.
Interestingly, the degree of reduction in neutrophil chemotaxis
achieved with the MAPK pharmacological inhibitors is greater
than the attenuation of IL-8 secretion. This may indicate that
other MAPK-dependent chemokines may also be upregulated by
S1P. Although IL-8 is the classical chemotaxin for neutrophils,
other chemokines such as GROa (CXCL1) and regulated on
activation normal T cell expressed and secreted (CCL5: also
known as RANTES) can also contribute to airway neutrophilia
[32]. These chemokines can be secreted by ASM cells [7,17,33,34]
and their expression is regulated by p38 MAPK/ERK- dependent
pathways [7,34,35]. We are the first to reveal the signaling
pathways activated by S1P in ASM cells [14,21], but based on our
demonstration that S1P induces IL-8 to enhance neutrophil
chemotaxis in a p38 MAPK/ERK-manner we predict that other
chemokines regulated by these signaling molecules may repressed
by pharmacological inhibition in a similar manner. This study
may have implications for revealing the pathogenic mechanisms
responsible for neutrophilic asthma endotype, although to date,
whether S1P levels are increased in BAL fluids from patients
characterised with neutrophilic asthma is an open question.
Together, these studies indicate that inflammatory mediators
such as S1P may contribute to the development of IL-8-driven
neutrophilia in airway inflammation and suggests that further
studies into the causal role played by S1P in the neutrophilic
asthma endotype are warranted.
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